BG Medicine (BGMD) Earns Daily Media Impact Rating of 0.20
Media stories about BG Medicine (NASDAQ:BGMD) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BG Medicine earned a news impact score of 0.20 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 44.2354216008758 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
BG Medicine (NASDAQ:BGMD) remained flat at $0.05 during mid-day trading on Wednesday. BG Medicine has a one year low of $0.03 and a one year high of $0.21. The stock’s market cap is $565950.00. The firm’s 50 day moving average price is $0.05 and its 200 day moving average price is $0.07.
BG Medicine Company Profile
BG Medicine, Inc (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation.
Receive News & Ratings for BG Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.